285MO The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma

Glioblastoma is a poorly immunogenic cancer and treatment options for recurrent glioblastoma are limited. Therefore, there is an urgent need for effective treatment strategies against recurrent glioblastoma. Here, we investigated a new treatment combination based on the tumor-stroma targeting antibody-cytokine fusion protein L19TNF and the alkylating chemotherapy lomustine in preclinical glioma models and patients with recurrent glioblastoma.